108Labs has announced the launch of its M2 smart bioreactor milk production platform. The company describes the platform as a “turnkey wetware, software, and hardware milk-making stack” designed to accelerate the scaling of cell-cultured milk.
According to the company, cell-cultured bovine milk has the potential to retire cows and slow global warming some day. It aims to accelerate the future of human milk and replacement dairy across many health and food product fields with the M2 platform.
108Labs is made up of several distinct entities including Pure Mammary Factors, M2Health and M2Foods.
Pure Mammary Factors was founded in December 2021 and aims to make product research and commercialisation in the field more affordable and accessible. Unlike raw milk, the company claims, its mammary cell medium and growth factors produce milks that are safe for human consumption right out of the cell without needing pasteurisation.
M2Health was founded in May 2020 and is developing therapeutic human milk for prescription drugs and humanised infant formula products, while M2Foods, founded in September 2021, is developing foods including bovine artisanal cheeses and other replacement dairy food products.
108Labs and 108Labs entities are licensing M2 and collaborating with dairy, food and pharmaceutical partners to accelerate Pure food and health products to market worldwide.
“What 108Labs has accomplished as a self-funded, family-run incubator over the last decade is astonishing, but the future is even more amazing and I couldn’t be more excited to work with Shayne and 108Labs on the future of food,” said Scott Matthews, COO, M2Foods.
